| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Jujuboside A targets GABA receptors by modulating GABA receptor subunit mRNA expression. It also promotes phosphorylation of PI3K, Akt, and mTOR and inhibits LC3 conversion, suggesting involvement in the PI3K/Akt/mTOR signaling pathway. It has neurophysiological inhibitory effects.
|
|---|---|
| ln Vitro |
In both the 24-hour and 72-hour treatments, jujuboside A at a low dose of 41 μM (around 0.05 g/L) significantly increased the mRNA for the GABA(A) receptor α1, α5, and β2 subunits. The levels of GABA(A) receptor α1 and α5 subunit mRNA were significantly increased and the level of β2 subunit mRNA was decreased after a 24-hour treatment with high-dose 82 μM (approximately 0.1 g/L) jujube glycoside A [1]. After a 72-hour treatment, GABA(A) Expression of mRNA of receptor subunits α1 and β2 was decreased. A pretreatment with jujuboside A can improve ISO damage to H9C2 cells and reverse the decline in cell viability. Jujuboside A has the ability to quicken PI3K, Akt, and mTOR phosphorylation. In H9C2 cells, jujuboside A has been shown to dramatically lower the ratio of microtubule-associated protein LC3-II/I [2].
In vitro, jujuboside A modulates GABA receptor subunit expression. It promotes phosphorylation of PI3K, Akt, and mTOR. It inhibits LC3 conversion, indicating potential autophagy modulation. It shows anti-proliferative and antioxidant activities. Specific IC₅₀ values are not extensively documented in the available literature. |
| ln Vivo |
Ziziphus seeds considerably enhanced both total and rapid eye movement (REM) sleep throughout the day (9:00–15:00), but had no discernible impact on non-rapid eye movement (NREM) sleep. Ziziphus spinosa seeds considerably improved non-REM sleep, particularly light sleep, and total sleep during the nighttime hours of 21:00–3:00, but had no discernible impact on REM sleep or slow-wave sleep (SWS) [ 3]. Aβ1-42-induced learning and memory impairment in mice was considerably reduced by intraventricular administration with Jujuboside A, as assessed by the Y-maze, Morris water maze, and active avoidance. Jujube glycoside A injected intracerebroventricularly can decrease hippocampal Aβ1-42 levels, significantly inhibit NO and acetylcholinesterase (AChE) activities, and lessen the elevated levels of malondialdehyde (MDA) in the cerebral cortex and hippocampus of mice. Aβ1-42[4].
In vivo, jujuboside A demonstrates sedative and hypnotic effects, reducing sleep latency and increasing sleep duration in animal models. It exhibits anxiolytic effects in behavioral models of anxiety. It shows neuroprotective and cardioprotective effects in animal models of ischemia or injury. |
| Enzyme Assay |
In vitro receptor binding assays use membrane preparations from brain tissue expressing GABA receptors. Radioligand binding studies with [³H]-muscimol or [³H]-flunitrazepam assess binding to GABA or benzodiazepine sites. Electrophysiological studies using patch-clamp or two-electrode voltage clamp in oocytes or neurons evaluate GABA receptor modulation.
|
| Cell Assay |
GABA receptor-expressing cell lines (e.g., HEK293, CHO cells transfected with receptor subunits) or primary neuronal cultures are used. Cells are treated with jujuboside A at various concentrations, and chloride influx is measured using fluorescent indicators or electrophysiological techniques. Cell viability and cytotoxicity are assessed by MTT assay.
|
| Animal Protocol |
In vivo efficacy is evaluated in rodent models of insomnia (e.g., pentobarbital-induced sleep test, caffeine-induced insomnia), anxiety (elevated plus maze, open field, light-dark box), and seizure (pentylenetetrazole or maximal electroshock seizure models). Jujuboside A is administered orally or intraperitoneally. Behavioral parameters are recorded and analyzed.
|
| ADME/Pharmacokinetics |
Jujuboside A has a molecular weight of approximately 1207.36. As a glycoside, it has moderate oral bioavailability. It undergoes metabolism by intestinal flora and hepatic enzymes. Specific pharmacokinetic parameters (half-life, Cmax) are not extensively documented in the available literature. It is typically used as a research compound.
|
| Toxicity/Toxicokinetics |
Jujuboside A is generally considered to have low toxicity based on traditional use of the source plant (Semen Ziziphi spinosae). No significant acute toxicity has been reported at doses used in research. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
See also: jujuboside A (note moved to).
Jujuboside A is a major bioactive saponin from Ziziphus jujuba var. spinosa seeds. It is widely used in traditional Chinese medicine for insomnia and anxiety. It has been extensively studied in preclinical research for its sedative, hypnotic, anxiolytic, and neuroprotective effects. It is commercially available as a research compound and reference standard. |
| Molecular Formula |
C58H94O26
|
|---|---|
| Molecular Weight |
1207.35
|
| Exact Mass |
1206.603
|
| CAS # |
55466-04-1
|
| PubChem CID |
53399223
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
222-225ºC
|
| Index of Refraction |
1.640
|
| LogP |
5.05
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
84
|
| Complexity |
2330
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KVKRFLVYJLIZFD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C58H94O26/c1-23(2)15-25-16-56(8,72)47-26-9-10-32-54(6)13-12-33(53(4,5)31(54)11-14-55(32,7)57(26)21-58(47,84-25)76-22-57)80-51-46(83-50-43(71)38(66)34(62)24(3)77-50)44(28(61)19-74-51)81-52-45(82-49-41(69)35(63)27(60)18-73-49)40(68)37(65)30(79-52)20-75-48-42(70)39(67)36(64)29(17-59)78-48/h15,24-52,59-72H,9-14,16-22H2,1-8H3
|
| Chemical Name |
2-[4-[4,5-dihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-5-hydroxy-2-[[16-hydroxy-2,6,6,10,16-pentamethyl-18-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosan-7-yl]oxy]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~82.83 mM)
H2O : ~50 mg/mL (~41.41 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (41.41 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8283 mL | 4.1413 mL | 8.2826 mL | |
| 5 mM | 0.1657 mL | 0.8283 mL | 1.6565 mL | |
| 10 mM | 0.0828 mL | 0.4141 mL | 0.8283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
